Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel-Reference-Cited by-同舟云学术

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel

Published:2022-07 Issue:11 Volume:23 Page:627-638
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Herrero Rivera Daniel¹^ORCID,Vacas Carmen Garrigós²^ORCID,Kovandzic Laura Marcos²,Vázquez Javier Puente³^ORCID,Alonso Lucía A⁴,González Begoña Mellado⁵^ORCID,Aragón Verónica Calderero⁶,Grande Enrique⁷^ORCID,Caro Raquel Luque⁸^ORCID,Virizuela Echaburu Juan A⁹^ORCID,Rodríguez Moreno Juan F¹⁰^ORCID,Etxebarria Ainara A¹¹^ORCID,Rodríguez-Antona Cristina¹²^ORCID,Durán Ignacio²⁴^ORCID

Affiliation:

1. Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, 41013, Spain. European University of Madrid, Madrid, 28670, Spain

2. Investigación Molecular y Traslacional en Oncología, Biomedicine Institute of Sevilla, IBiS/University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, 41013, Spain

3. Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, 28040, Spain

4. Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla de Santander, Santander, 39008, Spain

5. Department of Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona, 08036, Spain

6. Department of Medical Oncology, Hospital de Barbastro, Huesca, 22300, Spain

7. Department of Medical Oncology, MD Anderson Cáncer Center España, Madrid, 28033, Spain

8. Department of Medical Oncology, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs, Granada, 18014, Spain

9. Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, 41009, Spain

10. Oncology Unit, HM Sanchinarro Clara Campal Comprehensive Cancer Center, Madrid, 28050, Spain

11. Department of Pathology, Hospital Universitario Marqués de Valdecilla de Santander, Santander, 39008, Spain

12. Hereditary Endocrine Cancer Group, Spanish National Cancer Reaserch Center (CNIO), Madrid, 28029, Spain. ISCIII Center for Biomedical Reaserch on Rare Diseases (CIBERER), Madrid, 28029, Spain

Abstract

Background: The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: 56 SNPs in five genes ( CYP3A4, CYP3A5, ABCB1, TUBB1 and CYP2C8) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. Results: TUBB1-rs151352 (hazard ratio: 0.52) and CYP2C8-rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and CYP2C8-rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. ABCB1-rs17327624 correlated with severe toxicity ≥grade 3 (odds ratio: 8.56) and CYP2C8-rs11572093 with asthenia (odds ratio: 8.12). Conclusion: Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.

Funder

Consejería de Salud, Junta de Andalucía

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2022-0023

Reference30 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. European Commission. European cancer information system. https://ecis.jrc.ec.europa.eu

3. Sociedad Española Oncología Médica. Las cifras del cáncer en España (2022). https://seom.org/prensa/el-cancer-en-cifras

4. Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer

5. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm